Alterity Therapeutics Limited ATHE
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | 2.29% | -69.58% | |||
| Total Revenue | 2.29% | -69.58% | |||
| Cost of Revenue | 2.28% | 75.62% | |||
| Gross Profit | 2.29% | -74.88% | |||
| SG&A Expenses | 2.28% | 11.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 2.18% | -48.89% | |||
| Total Operating Expenses | 2.28% | 23.37% | |||
| Operating Income | -2.29% | -48.31% | |||
| Income Before Tax | -2.29% | -52.01% | |||
| Income Tax Expenses | 2.22% | -10.89% | |||
| Earnings from Continuing Operations | -2.28% | -51.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.28% | -51.60% | |||
| EBIT | -2.29% | -48.31% | |||
| EBITDA | -2.28% | -48.33% | |||
| EPS Basic | -2.27% | -41.94% | |||
| Normalized Basic EPS | -2.19% | -42.71% | |||
| EPS Diluted | -2.64% | -46.45% | |||
| Normalized Diluted EPS | -2.19% | -42.71% | |||
| Average Basic Shares Outstanding | 0.00% | 6.78% | |||
| Average Diluted Shares Outstanding | 0.00% | 6.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||